Navigation Links
Quest Diagnostics Completes Acquisition of Clinical Laboratory Partners' Outreach Laboratory Service Business in Connecticut

MADISON, N.J. and HARTFORD, Conn., Feb. 29, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of the outreach laboratory service business of Clinical Laboratory Partners (CLP), a wholly-owned subsidiary of Hartford HealthCare (HHC). HHC is an integrated health care system with five hospitals in Connecticut. Financial terms were not disclosed.

With the acquisition, people and providers in Connecticut will have broader access to quality, affordable and convenient laboratory services, with a broader network of patient service centers and three rapid-response clinical laboratories in the state. Physicians in Connecticut will also be able to order testing and consult with Quest Diagnostics' medical experts at Quest's full-service clinical laboratory in Marlborough, Mass. This lab provides state-of-the-art testing services, such as next-generation sequencing and bioinformatics, to aid the detection of cancer, dementia and other diseases.

HHC's hospital-based laboratories and the inpatient and outpatient services they provide are not included in the transaction and will remain part of the HHC system. Professional consultative pathology services performed by Hartford Pathology Associates are also not part of the acquisition.

This is the fifth acquisition of a laboratory outreach service business from a hospital system by Quest Diagnostics since 2012, when the company introduced its five-point strategy, which includes restoring growth and driving disciplined capital deployment through strategically-aligned, accretive acquisitions. The company has also formed several agreements with hospitals to provide professional laboratory services, such as lab management outsourcing. Quest's scale and expertise enable it to produce highly innovative test services cost-effectively, with fees that are often far lower than those of other providers for comparable services, according to independent research.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

Quest Diagnostics Contacts: 
Wendy Bost, Quest Diagnostics (Media): 973-520-2800 
Dan Haemmerle, Quest Diagnostics (Investors): 973-520-2900

Hartford HealthCare Contact:
Rebecca Stewart, Hartford HealthCare (Media): 860-972-4285

Logo -

SOURCE Quest Diagnostics
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
2. Quest Diagnostics To Speak At The 34th Annual J.P. Morgan Healthcare Conference
3. NeuroQuest to Begin US Clinical Validation Trials for Alzheimers Blood Test
4. Global Futurist Jack Uldrich Says, "Question the Future"
5. Quest Diagnostics Increases Share Repurchase Authority by $500 Million
6. Quest Diagnostics Declares Quarterly Cash Dividend
7. Kalorama: With Alzheimers Disease, A Quest to Know More Fuels Biomarker Search
8. Quest PharmaTechs Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer
9. Ditthavong & Steiner, P.C., Has Filed a Request for Investigation of Alleged Trademark Infringement by Apple Inc.
10. Delaware Soybean Board Releases Request for Research Proposals
11. Endo Provides Informational Frequently Asked Questions & Answers
Post Your Comments:
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... in the early detection and prevention of high-burden diseases, and Centric Consulting, a ... and healthcare organizations to utilize existing data in order to identify and prioritize ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., ... hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of ...
(Date:7/1/2020)... Colo. (PRWEB) , ... June ... ... of expert tissue data insights, today announced that the launch of a ... results along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight ...
Breaking Biology Technology:
(Date:7/4/2020)... ... , ... Aesthetics Biomedical (ABM), a leading aesthetics product development ... the products and treatments developed, but also the dedicated team behind the brands ... built by ABM have received several honors already for 2020, each of which ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a registered 501(c)(3) ... and aggressive adult brain cancer—announced today the appointments of its first Senior Fellows: ... supporting the organization’s initiatives and overall vision. , "Senior Fellows are more than ...
(Date:6/23/2020)... Md. (PRWEB) , ... June ... ... leading provider of gene-to-protein and monoclonal antibody development services, today announced that ... protein-based products and services to the pharmaceutical, diagnostics, and research industries. The ...
Breaking Biology News(10 mins):